APA (7th ed.) Citation

Lewis, D. J., Jerkeman, M., Sorrell, L., Wright, D., Glimelius, I., Poulsen, C. B., . . . Allgar, V. (2025). Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): A randomised, open-label, phase 2/3 superiority trial. Lancet, 406(10514), 1953. https://doi.org/10.1016/S0140-6736(25)01432-1

Chicago Style (17th ed.) Citation

Lewis, David J., et al. "Ibrutinib and Rituximab Versus Immunochemotherapy in Patients with Previously Untreated Mantle Cell Lymphoma (ENRICH): A Randomised, Open-label, Phase 2/3 Superiority Trial." Lancet 406, no. 10514 (2025): 1953. https://doi.org/10.1016/S0140-6736(25)01432-1.

MLA (9th ed.) Citation

Lewis, David J., et al. "Ibrutinib and Rituximab Versus Immunochemotherapy in Patients with Previously Untreated Mantle Cell Lymphoma (ENRICH): A Randomised, Open-label, Phase 2/3 Superiority Trial." Lancet, vol. 406, no. 10514, 2025, p. 1953, https://doi.org/10.1016/S0140-6736(25)01432-1.